**Passenger mutations in >2500 cancer genomes: Overall burdening & selective effects**

Whole genome sequencing gives us an unprecedented window into the variation profile of cancer genomes. The overwhelming majority of these variants occur in noncoding regions of the genome. However, in a simplified, classic view of cancer progression, most of these variants confer no selective advantage to the cancer cell and are considered to occur neutrally. In contrast, a handful of driver variants are thought to give a positive selection advantage to the cancer cell. This canonical dichotomy is often useful, but it is also imprecise. A more nuanced view admits that some passenger variants may impact tumor cell biology along a range of dimensions and weakly affect tumor cell fitness for better or for worse. The fact that passenger variants’ selective effects are *individually* weak does not imply that passengers’ *overall* selective effects are unimportant: with thousands of passenger variants in a typical tumor, the overall burden of passenger variants may be considerable in aggregate.

 The PCAWG variant dataset, which comprises comprehensive pan-cancer variant calls from ~2700 uniformly processed whole cancer genomes, gives us an unparalleled opportunity to investigate this hypothesis. Given that the majority of passenger variants lie in non-coding regions, this variant dataset serves as a substantially more informative resource than the many existing datasets focused on exomes. In addition, it also contains a full spectrum of variants, including copy number variants (CNVs) and large structural variants (SVs) in addition to SNVs and INDELs. In this work, our purposes are two-fold: First, we build on and apply existing tools to score the predicted biological impact of each variant, including SNVs, INDELs and SVs in the pan-cancer dataset. Subsequently, we search for signals of positive and negative selection of passenger variants, particularly those we predict to be impactful.

We find seven forms of evidence for selection upon passenger variants. We find that the distribution of impact scores among passenger variants, their mutational signatures, variant allele frequencies, co-mutation frequencies, ability to predict age of cancer onset (in the case of germline variants) and patient survival, and inferred evolutionary timing contradict our null hypothesis that all passenger variants are neutral.

In order to substantiate the presence of passenger variants undergoing selection, we surveyed the functional impact distribution of somatic variants in the pan-cancer dataset. If the bulk of variants in cancer were occurring neutrally, one would expect a unimodal distribution, with a large peak at low impact value and a tail in high impact regime corresponding to neutral passengers and positively selected putative driver variants, respectively. However, the distribution of impact scores for somatic variants across cancer cohorts exhibits a very different pattern, wherein variants can be broadly resolved into three distinct subgroups. The upper and the lower extremes (which comprise ~23 and ~13,500 noncoding variants per patient, respectively), fall under traditional definitions of high-impact putative driver variants and neutral passengers, respectively. In contrast, the intermediate functional impact regime comprises what we term *impactful* *passengers* (~3,500 noncoding variants per patient). Furthermore, we observe a heterogeneous enrichment profile of these non-neutral passengers in different cancer-subtypes and different categories of genes. Cohort level analysis indicates enrichment of non-neutral passenger SNVs in various cancer types compared with randomized mutation sets which represent a neutral background. Myeloid-MPN, colorectal and uterine adenocarcinoma cohorts stood out with the highest enrichment level of non-neutral passengers.

Highly disruptive loss-of-function (LOF) variants (both SNVs and INDELs) highlights the role of positive selection in cancer progression. A gene-centric analysis of LOFs indicate that they are highly enriched among essential genes in the entire pan-cancer dataset. Intuitively, one would expect no such enrichment of neutral passenger variants among essential genes. However, we observe a relatively high fraction of non-neutral impactful passenger variants in key genes (essential, metabolic & immune-response genes) compared to low impact neutral passenger variants. Conversely, neutral passengers constitute larger fractions of variants influencing non-essential genes. This observation is consistent with previous studies suggesting role of non-neutral passenger variants in cancer progression by burdening key genes including housekeeping, metabolic and immune-response genes.

Furthermore, we inspected the signature composition of neutral and non-neutral passengers in each cancer-cohort to distinguish between mutational processes that generate these distinct classes of passenger variants. For instance, we observed distinct signature distributions for the impactful and neutral non-coding passengers in the Kidney-RCC cohort. While the majority of neutral and non-neutral passengers can be explained by signature 5, impactful passengers have a higher fraction of SNVs explained by signature 4. This suggests that non-neutral passenger SNVs show shifts in mutational signatures compared to the neutral ones.

One might further expect that neutral passenger variants will be uniformly distributed contributing uniform functional burden across the genome. Consequently, we comprehensively analyzed the overall mutational burdening of various genomic elements, including TF (transcription factor) binding motifs in the pan-cancer somatic variant dataset. The presence of a variant within a TF binding site can lead to either the creation or destruction of binding motifs (gain or loss of function). In both cases, we observe significant differential burdening of *impactful variants* among different cancer cohorts. For instance, we observe significant enrichment of high impact variants creating new motifs in various TFs such as GATA, PRRX2 and SOX10 across major cancer types analyzed in this study. Similarly, high impact variants influencing gene expression by breaking TF motifs, were highly enriched in YY1, BCL, RAD21 and CTCF in a majority of cohorts. This selective enrichment or depletion suggests distinct alteration profiles associated with different components of regulatory networks in various cancers. Furthermore, signature analysis of these variants influencing TF binding sites suggests that distinct signatures burden motifs disproportionately. For instance, the underlying mutation spectrum of motif breaking events observed in SP1 TF binding sites (TFBS) suggest major contribution from C>T and C>A mutation. In contrast, motif breaking events at TFBS of HDAC2 and EWSR1 have relatively uniform mutation spectrum profiles.

In addition to SNVs, SVs are also believed to play a pivotal role in driving cancer progression. Thus we annotated and evaluated the impact of large SVs in the entire PCAWG cohort. In a neutral model, we would expect majority of SVs to be distributed across the genome regardless of their extent of overlap with functional elements of the genome. However, our annotation analysis of somatic SVs in PCAWG portrays a different picture. We observe significant enrichment of large engulfing somatic deletions as well as duplications among pseudogenes, coding regions, UTRs and TF peak regions. Moreover, engulfing SVs tend to have higher enrichment value compared to partially overlapping SVs. The observed enrichment bias of SVs toward certain regions of the genome as well as the extent of their overlap suggest that selection processes play a key in role in emergence of somatic SVs. We quantified the effect of these selection processes by evaluating functional impact of these large deletions and duplications across various cancer-types. The functional impact score distribution of SVs for different cancer-types indicate that meta tumor cohorts such as CNS, glioma and sarcoma tend to harbor higher impact large deletions and duplications compared to others. In addition, gene-centric analysis on the pan-cancer level reveals that CDKN2A and TEKT2 genes have the largest observed enrichment of high impact deletions and duplications, respectively.

Additionally, we also explored the role of impactful variations in cancer evolution by integrating them with subclonal information and allele frequencies. Intuitively, one might hypothesize that high impact mutations should either achieve higher frequency if they are advantageous to the tumor, or a lower frequency if deleterious. Interestingly, one finds suggestive observations that this is the case. In particular, we observe that high functional impact non-coding variants (along with high impacting coding LOF variants) have a higher allelic frequency and a higher prevalence in parental subclones, signifying a potential important role in the early phases of cancer progression or providing a higher fitness advantage.

Furthermore, co-mutation analysis supports the selected passenger hypothesis. If passenger mutations were under no selection, then we would expect their co-mutation frequencies to depend predictably on their individual mutation rates and the mutational burdens of the involved patients. However, we observe more instances of high co-mutation among passenger variants than expected by chance in Medulloblastoma and some other cancer subtypes. Pan-cancer, we observe significantly anti-correlated passenger gene-pairs. One interesting observation from this analysis is that anti-correlated gene-pairs are substantially more likely to participate in the same pathway than are randomly chosen gene-pairs, which is consistent with plausible mechanisms by which gene-pairs may confer redundant or synergistic selective effects. Example mechanisms are schematized in Figure XXX.

Finally, we sought to examine whether impactful passengers might exert a clinically meaningful effect on tumor initiation and progression. Therefore, we correlated patient impactful somatic mutation burden with patient age at diagnosis and patient impactful germline mutation burden with patient survival. We observed that patients harboring a larger number of high-impact rare germline alleles were diagnosed with cancer at earlier ages in three cancer subtypes. We then performed survival analysis to see if somatic impact burden –the ranked sum of the impact scores of coding and noncoding variants – predicted patient survival within individual cancer subtypes. These correlations varied substantially in different cancer types. For instance, we observed that somatic mutation burden predicted substantially earlier death in chronic lymphocytic leukemia (CLL) and substantially prolonged survival in renal cell carcinoma (RCC), respectively. These observations remained after redefining somatic impact burden in relation to the burdening of corresponding randomized sets. Furthermore, these patterns remained after adjusting for patient age at diagnosis, low-impact mutation load, and –in the case of CLL, including a covariate for IgVH mutation status. These results lend support to the hypothesis that the aggregate amount of impactful passengers is clinically meaningful. More specifically, these results suggest that latent drivers are more important than deleterious passengers in CLL, but that the situation is reversed in RCC. This can be explained by the large share of missing drivers in CLL, which suggests a greater role for latent drivers in CLL.

In conclusion, our work highlights an important subset of somatic variants originally identified as passengers nonetheless show biologically and clinically relevant functional roles across a range of cancers.